Syndax Pharmaceuticals (SNDX) Total Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Liabilities history runs 12 years deep, the most recent figure standing at $431.0 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 1.27% year-over-year to $431.0 million; the TTM figure through Mar 2026 stood at $431.0 million (up 1.27% YoY), while the FY2025 annual figure was $465.1 million, up 6.5% from the prior year.
• Total Liabilities was $431.0 million for Q1 2026 at Syndax Pharmaceuticals, down from $465.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $465.1 million in Q4 2025 to a low of $21.6 million in Q3 2022.
• Historically, Total Liabilities has averaged $181.4 million across 5 years, with a median of $51.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities sank 48.98% in 2023, then jumped 929.65% in 2025.
• A 5-year view of Total Liabilities shows it stood at $29.8 million in 2022, then soared by 97.01% to $58.7 million in 2023, then soared by 644.14% to $436.7 million in 2024, then increased by 6.5% to $465.1 million in 2025, then slipped by 7.32% to $431.0 million in 2026.
• The last three Total Liabilities figures came in at $431.0 million (Q1 2026), $465.1 million (Q4 2025), and $436.4 million (Q3 2025), per Business Quant data.